Founded Year
1993Stage
Acq - P2P | AcquiredTotal Raised
$131.86MAbout Guilford Pharmaceuticals
Guilford Pharmaceuticals is a pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Guilford's marketed products include the Gliadel Wafer for brain tumor treatment, and their product pipeline includes a novel anesthetic, Aquavan Injection.
Missing: Guilford Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Guilford Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Guilford Pharmaceuticals
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Guilford Pharmaceuticals is included in 1 Expert Collection, including Cancer.
Cancer
1,179 items
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Guilford Pharmaceuticals Patents
Guilford Pharmaceuticals has filed 1 patent.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/25/2003 | 1/20/2009 | Polymers, Drug delivery devices, Nanomaterials, Dosage forms, Membrane biology | Grant |
Application Date | 2/25/2003 |
|---|---|
Grant Date | 1/20/2009 |
Title | |
Related Topics | Polymers, Drug delivery devices, Nanomaterials, Dosage forms, Membrane biology |
Status | Grant |
Guilford Pharmaceuticals Frequently Asked Questions (FAQ)
When was Guilford Pharmaceuticals founded?
Guilford Pharmaceuticals was founded in 1993.
Where is Guilford Pharmaceuticals's headquarters?
Guilford Pharmaceuticals's headquarters is located at 6611 Tributary Street, Baltimore.
What is Guilford Pharmaceuticals's latest funding round?
Guilford Pharmaceuticals's latest funding round is Acq - P2P.
How much did Guilford Pharmaceuticals raise?
Guilford Pharmaceuticals raised a total of $131.86M.
Who are the investors of Guilford Pharmaceuticals?
Investors of Guilford Pharmaceuticals include MGI Pharma, Domain Associates, Merlin Biomed Group, Highbridge Capital Management, Quogue Capital and 34 more.
Who are Guilford Pharmaceuticals's competitors?
Competitors of Guilford Pharmaceuticals include Bellus Health, Aquinox Pharmaceuticals, Auxilium Pharmaceuticals, Cadence Pharmaceuticals, Topaz Pharmaceuticals and 13 more.
Compare Guilford Pharmaceuticals to Competitors
IVREA Pharmaceuticals is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. IVREA's pharmaceuticals leverage topical delivery technologies.
Frio Pharmaceuticals is dedicated to oral-systemic health and was spun out of Biomedical Development Corporation (BDC), its research affiliate, in 1999 to manufacture and sell a dental waterline cleaner. This platform technology has evolved into a pipeline of pharmaceuticals to treat oral diseases and interrupt the disease process. Its goal is to commercialize a broad-spectrum antimicrobial platform technology with products being: (1) a pharmaceutical to treat thrush (oral candidiasis) in cancer patients with thrush and (2) a pharmaceutical to treat gingivitis (oral inflammation).
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
A European specialty pharmaceutical company dedicated to hospital and specialist drugs.SpePharm is a European specialty pharmaceutical company focused on acquiring, registering and marketing high medical value specialty medicines, essentially for the hospital market.
Slate currently markets Testopel in the United States. Testopel is an FDA-approved subcutaneous implantable testosterone pellet. Testopel is used for the treatment of testosterone deficiency in aging men as well as androgen deficiency caused by other conditions.
Urigen specializes in the design and commercialization of innovative products for patients with urological ailments. The company develops products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.